moclobemide has been researched along with harmaline in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Bizière, K; Kan, JP; Mouget-Goniot, C; Steinberg, R; Worms, P | 1 |
| Gerardy, J | 1 |
3 other study(ies) available for moclobemide and harmaline
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
Topics: Animals; Benzamides; Biogenic Amines; Brain; Clorgyline; Dopamine; Duodenum; Harmaline; Isoenzymes; Liver; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxazoles; Oxazolidinones; Pyridazines; Rats; Selegiline; Synaptosomes | 1987 |
Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
Topics: Animals; Benzamides; Brain; Clorgyline; Harmaline; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Rats; Rats, Wistar | 1994 |